Symbiotec Pharmalab IPO Allotment Today: How to Check Status on NSE, BSE and MUFG Intime India; Listing Date

The Symbiotec Pharmalab IPO was subscribed 71.26 times overall, with strong demand from qualified institutional buyers. The basis of allotment is expected to be finalised on Friday, August 28, 2026.

Investors who applied for shares in the Symbiotec Pharmalab IPO are awaiting the finalisation of the basis of allotment, which is expected on Friday, August 28, 2026.

Applicants will be able to check their IPO allotment status online through the websites of the issue registrar, MUFG Intime India, as well as the National Stock Exchange (NSE) and the BSE.

The public issue witnessed exceptionally strong investor participation, recording an overall subscription of 71.26 times. According to the subscription figures, the IPO received bids for 93,52,49,700 shares against 1,31,24,929 shares offered for subscription.

The Qualified Institutional Buyers category recorded the highest level of demand, while the non-institutional and retail investor portions were also subscribed multiple times.

Symbiotec Pharmalab IPO Subscription Status

The IPO saw strong demand across all major investor categories.

The QIB category was subscribed 172.03 times, making it the most heavily subscribed segment of the public issue.

The NII category received subscriptions of 73.63 times, while the retail investor portion was subscribed 12.96 times.

The final number of shares allotted to successful applicants will depend on the basis of allotment and the applicable allocation process.

Symbiotec Pharmalab IPO Allotment Date

The basis of allotment for the Symbiotec Pharmalab IPO is expected to be finalised on Friday, August 28, 2026.

Allotment information may become available after the registrar completes the finalisation process. Investors should check the official platforms for the latest status and should note that processing timelines may vary.

Applicants can generally verify their status using details such as:

• PAN
• IPO application number
• DP ID and Client ID
• Bank account details, where applicable

How to Check Symbiotec Pharmalab IPO Allotment Status on NSE

Investors can check the allotment status through the National Stock Exchange’s IPO application details section.

Follow these steps:

1. Visit the official NSE IPO application or bid details page.
2. Select “Equity & SME IPO bid details.”
3. Choose “SYMBIOTEC” from the available symbols, once displayed.
4. Enter your application number.
5. Enter your PAN (Permanent Account Number) if required.
6. Complete the required verification process.
7. Click or press Submit to view the application status.

The NSE portal may display information about whether the application has received an allotment, depending on the availability of finalised data.

How to Check Symbiotec Pharmalab IPO Allotment Status on BSE

Investors can also check the IPO allotment status through the BSE allotment verification facility.

The process generally involves:

1. Visiting the official BSE IPO allotment status page.
2. Selecting “Equity” as the issue type.
3. Choosing “Symbiotec Pharmalab Ltd” from the list of IPOs, when available.
4. Entering the IPO application number or PAN.
5. Completing any required verification.
6. Clicking “Search.”

The result should show the available allotment information after the basis of allotment has been finalised and uploaded.

How to Check Symbiotec Pharmalab IPO Allotment Status on MUFG Intime India

The IPO registrar, MUFG Intime India, is another official platform through which applicants can check their allotment status.

Investors can follow these general steps:

1. Visit the official IPO allotment status page of MUFG Intime India.
2. Select “Symbiotec Pharmalab Limited” from the list of available public issues.
3. Choose one of the available identification methods.
4. Enter any required details, which may include:
   • DP ID and Client ID
   • PAN
   • Account number and IFSC
   • IPO application number
5. Complete the verification process, if applicable.
6. Click “Submit.”

The allotment result will be displayed when the final data is available on the registrar’s platform.

Symbiotec Pharmalab IPO Listing Date

Shares of Symbiotec Pharmalab are scheduled to list on the NSE and BSE on Tuesday, September 1, 2026, subject to the completion of the applicable listing and settlement process.

Investors should check official exchange notices for the confirmed listing schedule.

The listing price will be determined by market demand when trading begins and may differ from the IPO issue price.

What Happens After IPO Allotment?

Once the basis of allotment is finalised, successful applicants are expected to receive shares in their demat accounts according to the applicable IPO settlement schedule.

For unsuccessful applications, the blocked funds are generally released or unblocked according to the ASBA and UPI application process and the relevant banking procedures.

Applicants should verify the status of:

• Share allotment
• Demat account credit
• Release of blocked funds
• Bank account status
• Official exchange announcements

Processing times can vary depending on the application method and financial intermediary involved.

Symbiotec Pharmalab IPO: Issue Size and Structure

The initial public offering sought to raise approximately ₹1,757 crore.

The issue included:

• A ₹150 crore fresh issue
• A ₹1,607 crore offer for sale (OFS)

Under the offer for sale, existing stakeholders, including Satwani Holdings LLP, India Business Excellence Fund – III and Rosewood Investments, offered shares for sale.

The fresh issue proceeds are proposed to be used for purposes including:

• Repayment of certain borrowings
• General corporate purposes

Investors should distinguish between a fresh issue and an offer for sale when analysing an IPO.

In a fresh issue, the company receives the funds raised through the new shares, subject to the stated use of proceeds. In an OFS, the proceeds generally go to the selling shareholders rather than the company.

What Does Symbiotec Pharmalab Do?

Symbiotec Pharmalab, incorporated in 2002, operates in the pharmaceutical and biotechnology sector.

The company develops and manufactures products including:

• Active Pharmaceutical Ingredients (APIs)
• Nutritional ingredients
• Speciality products

The pharmaceutical and biotechnology sectors are closely linked to healthcare manufacturing and global supply chains. Companies in this segment may be exposed to factors such as regulatory requirements, customer concentration, raw-material costs, product approvals and international market conditions.

Potential investors should review the company’s official offer documents for detailed information about its operations, financial performance, risk factors and business strategy.

Why Was the IPO Subscription So High?

The IPO’s overall subscription level of 71.26 times indicates substantial demand relative to the number of shares offered.

The strongest participation came from QIBs, followed by NIIs and retail investors.

However, a high subscription figure should not be considered a guarantee of listing gains or future investment returns.

IPO subscription numbers measure the level of demand for shares during the bidding period. The market performance of a company’s shares after listing can depend on several factors, including:

• Overall stock market conditions
• Company financial performance
• Industry outlook
• Valuation
• Investor sentiment
• Future earnings growth
• Listing-day demand

Investors should therefore avoid relying only on subscription figures or unofficial market indicators when evaluating an investment.

Symbiotec Pharmalab IPO: Key Dates at a Glance

Investors should verify any changes to these dates through official announcements from the stock exchanges, registrar or other authorised sources.

Symbiotec Pharmalab IPO Allotment: The Bottom Line

The Symbiotec Pharmalab IPO attracted strong investor interest, with the public issue subscribed 71.26 times overall. Institutional demand was particularly strong, with the QIB category receiving bids equivalent to 172.03 times the shares reserved for that segment.

The basis of allotment is expected to be finalised on August 28, 2026, and investors can check the status through the official platforms of MUFG Intime India, NSE and BSE after the information becomes available.

Applicants should use only official websites and ensure that they enter sensitive information, such as PAN or application details, on trusted platforms.

The company’s shares are scheduled to list on the NSE and BSE on September 1, 2026, subject to the completion of the applicable process and official exchange confirmation.